Cape Cod Five Cents Savings Bank Has $1.68 Million Holdings in Bristol-Myers Squibb Co (BMY)
Cape Cod Five Cents Savings Bank cut its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 13.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,385 shares of the biopharmaceutical company’s stock after selling 3,960 shares during the period. Cape Cod Five Cents Savings Bank’s holdings in Bristol-Myers Squibb were worth $1,682,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. First Trust Advisors LP raised its holdings in shares of Bristol-Myers Squibb by 10.7% during the 2nd quarter. First Trust Advisors LP now owns 433,050 shares of the biopharmaceutical company’s stock worth $24,130,000 after buying an additional 41,892 shares in the last quarter. Oppenheimer & Co. Inc. raised its holdings in shares of Bristol-Myers Squibb by 2.5% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 358,509 shares of the biopharmaceutical company’s stock worth $19,976,000 after buying an additional 8,813 shares in the last quarter. Israel Discount Bank of New York raised its holdings in shares of Bristol-Myers Squibb by 31.8% during the 2nd quarter. Israel Discount Bank of New York now owns 10,515 shares of the biopharmaceutical company’s stock worth $586,000 after buying an additional 2,540 shares in the last quarter. Dividend Assets Capital LLC acquired a new position in shares of Bristol-Myers Squibb during the 2nd quarter worth $737,000. Finally, State Street Corp raised its holdings in shares of Bristol-Myers Squibb by 1.8% during the 1st quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after buying an additional 1,223,457 shares in the last quarter. 69.66% of the stock is owned by hedge funds and other institutional investors.
In related news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the business’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the sale, the executive vice president now owns 9,251 shares in the company, valued at approximately $585,033.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Theodore R. Samuels II acquired 4,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, December 15th. The shares were purchased at an average price of $62.30 per share, for a total transaction of $249,200.00. Following the transaction, the director now directly owns 22,000 shares in the company, valued at $1,370,600. The disclosure for this purchase can be found here. Insiders own 0.23% of the company’s stock.
BMY has been the subject of a number of research analyst reports. Jefferies Group reissued a “buy” rating and set a $72.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday, September 27th. Vetr raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.50 price target for the company in a report on Wednesday, September 27th. UBS Group reissued a “buy” rating and set a $72.00 price target (up previously from $62.00) on shares of Bristol-Myers Squibb in a report on Friday, October 6th. Citigroup boosted their price target on Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a report on Wednesday, October 18th. Finally, SunTrust Banks raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Monday, October 30th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $64.42.
Shares of Bristol-Myers Squibb Co (NYSE BMY) opened at $61.89 on Friday. The firm has a market capitalization of $101,300.00, a price-to-earnings ratio of 24.37, a P/E/G ratio of 2.21 and a beta of 1.18. Bristol-Myers Squibb Co has a 52-week low of $46.01 and a 52-week high of $66.10. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The firm had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company’s revenue was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.77 EPS. analysts forecast that Bristol-Myers Squibb Co will post 2.99 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, January 4th. This represents a $1.60 dividend on an annualized basis and a yield of 2.59%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s payout ratio is currently 61.42%.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with Analyst Ratings Network's FREE daily email newsletter.